ATE448242T1 - Gamma-sekretase-inhibitoren - Google Patents

Gamma-sekretase-inhibitoren

Info

Publication number
ATE448242T1
ATE448242T1 AT03720938T AT03720938T ATE448242T1 AT E448242 T1 ATE448242 T1 AT E448242T1 AT 03720938 T AT03720938 T AT 03720938T AT 03720938 T AT03720938 T AT 03720938T AT E448242 T1 ATE448242 T1 AT E448242T1
Authority
AT
Austria
Prior art keywords
val
group
leu
alkyl
ile
Prior art date
Application number
AT03720938T
Other languages
English (en)
Inventor
Hiroshi Mori
Original Assignee
Hiroshi Mori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroshi Mori filed Critical Hiroshi Mori
Application granted granted Critical
Publication of ATE448242T1 publication Critical patent/ATE448242T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03720938T 2002-04-24 2003-04-18 Gamma-sekretase-inhibitoren ATE448242T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002121983 2002-04-24
PCT/JP2003/005017 WO2003091278A1 (fr) 2002-04-24 2003-04-18 Inhibiteurs de gamma secretase

Publications (1)

Publication Number Publication Date
ATE448242T1 true ATE448242T1 (de) 2009-11-15

Family

ID=29267426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03720938T ATE448242T1 (de) 2002-04-24 2003-04-18 Gamma-sekretase-inhibitoren

Country Status (11)

Country Link
US (1) US7585938B2 (de)
EP (1) EP1498421B1 (de)
JP (1) JP4404643B2 (de)
KR (1) KR101051249B1 (de)
CN (1) CN1319987C (de)
AT (1) ATE448242T1 (de)
AU (1) AU2003235283A1 (de)
BR (1) BR0304562A (de)
DE (1) DE60329995D1 (de)
NO (1) NO329184B1 (de)
WO (1) WO2003091278A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2007316597B2 (en) * 2006-11-07 2013-01-31 Katholieke Universiteit Leuven, K. U. Leuven R & D Diagnosis and treatment of T-cell acute lymphoblastic leukemia
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
EP2177529B1 (de) * 2007-08-09 2013-03-27 Kabushiki Kaisha Yakult Honsha Gamma-sekretasehemmer
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
WO2012144972A2 (en) * 2010-01-19 2012-10-26 The General Hospital Corporation Methods to inhibit neurodegeneration
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
CN102344485A (zh) * 2010-08-05 2012-02-08 中国人民解放军军事医学科学院毒物药物研究所 用于治疗阿尔茨海默病的肽类β分泌酶抑制剂及其用途
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
EP3461819B1 (de) 2017-09-29 2020-05-27 Probiodrug AG Hemmer der glutaminylcyclase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI870474A (fi) 1986-02-07 1987-08-08 Ciba Geigy Ag Med svavelhaltiga grupper substituerade 5-amino-4-hydroxivalerylderivat.
EP1254108A1 (de) 2000-01-24 2002-11-06 MERCK SHARP & DOHME LTD. Gamma-sekretase-inhibitoren
US6753410B2 (en) * 2000-03-02 2004-06-22 Merck & Co., Inc. Investigational compounds
AU2001261368A1 (en) * 2000-05-11 2001-11-20 Scios Inc. Modulation of gamma-secretase activity
US20030022251A1 (en) * 2001-07-04 2003-01-30 Boehringer Ingelheim Pharma Kg Gamma-secretase in vitro screening assay

Also Published As

Publication number Publication date
US7585938B2 (en) 2009-09-08
WO2003091278A1 (fr) 2003-11-06
KR101051249B1 (ko) 2011-07-21
NO20035535D0 (no) 2003-12-11
EP1498421A1 (de) 2005-01-19
NO20035535L (no) 2004-02-19
EP1498421A4 (de) 2006-05-17
AU2003235283A1 (en) 2003-11-10
KR20040106370A (ko) 2004-12-17
CN1656115A (zh) 2005-08-17
EP1498421B1 (de) 2009-11-11
JP4404643B2 (ja) 2010-01-27
JPWO2003091278A1 (ja) 2005-09-02
CN1319987C (zh) 2007-06-06
BR0304562A (pt) 2004-07-20
US20060205666A1 (en) 2006-09-14
NO329184B1 (no) 2010-09-06
DE60329995D1 (de) 2009-12-24

Similar Documents

Publication Publication Date Title
DE60329995D1 (de) Gamma-sekretase-inhibitoren
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
BR0114147A (pt) Uso de tensoativos catiÈnicos em preparações cosméticas
RS54847B1 (sr) Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida
AR038383A1 (es) Compuesto inhibidor de la hepatitis c
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
PE107299A1 (es) Composiciones farmaceuticas que comprenden un analogo de gaba y un antiinflamatorio no esteroideo
ATE331708T1 (de) Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
SG50602A1 (en) Novel heterocyclic compound
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
BR0307060A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
IS7482A (is) Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf
MX9705559A (es) Derivados de acido neuraminico, su preparacion y su uso en medicina.
HRP20080330T3 (en) Antitumoral compounds based on kahalalide f
WO2001072263A3 (de) Verwendung von ectoin oder ectoin-derivaten zum schutz der stressprotein in der haut
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
PT1226160E (pt) Novos peptidos antiarritmicos
DK0624586T3 (da) Substituerede pyrroler
EP2266971A3 (de) HIV-Protease inhibierende Verbindungen
DE59900730D1 (de) Korrosionsinhibitoren enthaltender Injektionszement
DK1309535T3 (da) Fremgangsmåder til fremstilling af alfa'-chlorketoner
DK1474439T3 (da) Dipeptider og tripeptider med anti-inflammatorisk virkning
HRP20050242B1 (en) Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs
AU2003245979A1 (en) Amides of cyclic amino acids used as pde 4 inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties